NDA


Also found in: Dictionary, Medical, Legal, Acronyms, Wikipedia.

NDA

(Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any other purpose. NDAs are signed for myriad reasons including when source code is handed to another party for modification or when a new product under development is being reviewed by the press, a prospective customer or other party.
References in periodicals archive ?
While NDTV showed that the NDA was ahead in 88 seats as against Grand Alliance in 57 of 150 seats, ABP said the NDA was leading in 75 seats while the Grand alliance was ahead in 70 seats out of 149.
The CNN-IBN CSDS-Lokniti exit poll suggests that NDA will get a lion's share of around 270-282 seats while the UPA will get around 92-102 seats only.
The FDA takes, on average, about a year to review a typical, non-expedited NDA, give or take a few months.
Subject to acceptance of the full NDA for review, INEX expects to have a response from the FDA within six months.
From mid-1989 to mid-1991 the SPLM/SPLA did not perceive NDA support as important.
The FDA plans to maintain indefinitely a PDF library of NDA submissions and review documents, giving it an easy-to-manage repository of drug history information, which is especially useful since drug manufacturers frequently submit changes -- for new dosages, different therapeutic applications -- to already approved medications.
Pesticide/fertilizer management: NDA staff from the Pesticide/Fertilizer program will be in the
Oil activities, NDA advanced Charter and Resolutions, NW hateful terrorism and greed, and the isolation of NW-controlled government have now created a new situation and new possibilities to handle the Sudanese Africans vs.
The agreement provides for the commercialization by Inspire of AzaSite[TM] (1% azithromycin), InSite's topical anti-infective product currently under NDA review by the FDA for the treatment of bacterial conjunctivitis; commonly referred to as "pink eye".
With this renewed agreement, NDA will be able to continue sponsoring "News Papers in Education" a young reader related program by offering affordable reading materials to students.
According to the company, its proposed efficacy and safety data for the tasimelteon NDA for Non-24 includes data from clinical pharmacology, pre-clinical pharmacology programme, chemistry and manufacturing.